Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant stateGloria V. Echeverria, Helen Piwnica‐Worms, Zhongqi Ge et al.|Science Translational Medicine|2019Cited by 316
AKT in cancer: new molecular insights and advances in drug developmentPrabhjot S. Mundi, Kevin Kalinsky, Jasgit C. Sachdev et al.|British Journal of Clinical Pharmacology|2016Cited by 267
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Meghna S. Trivedi et al.|Journal of Clinical Oncology|2022Cited by 73